Elizabeth Parker | IR, KCSA Strategic Communications |
Carl Schwartz | CEO |
Gerry Vardzel | CEO, Helomics Corporation |
Bob Myers | CFO |
Good day, everyone, and welcome to the Precision Therapeutics Q2 2018 Business Update. Today's conference is being recorded. And at this time, I would like to turn the call over to Elizabeth Parker, Investor Relations at KCSA Strategic Communications. Please go ahead.
Thank you all for participating in today's call to discuss Precision Therapeutics financial results for the second fiscal quarter of 2018.